RhumbLine Advisers
JANX icon

RhumbLine Advisers’s Janux Therapeutics JANX Stock Holding History

RhumbLine Advisers’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$848K Buy
55,221
+2,584
+5% +$37.4K ﹤0.01% 2421
2026
Q1 		$732K Buy
52,637
+276
+0.5% +$3.79K ﹤0.01% 2370
2025
Q4 		$723K Sell
52,361
-5,283
-9% -$124K ﹤0.01% 2421
2025
Q3 		$1.41M Sell
57,644
-1,747
-3% -$42.5K ﹤0.01% 2076
2025
Q2 		$1.37M Buy
59,391
+16,741
+39% +$441K ﹤0.01% 2092
2025
Q1 		$1.15M Buy
42,650
+4,497
+12% +$170K ﹤0.01% 2101
2024
Q4 		$2.04M Buy
38,153
+599
+2% +$31.7K ﹤0.01% 1865
2024
Q3 		$1.71M Sell
37,554
-454
-1% -$19.8K ﹤0.01% 1994
2024
Q2 		$1.59M Buy
38,008
+11,085
+41% +$520K ﹤0.01% 2004
2024
Q1 		$1.01M Buy
26,923
+838
+3% +$18.3K ﹤0.01% 2242
2023
Q4 		$280K Sell
26,085
-447
-2% -$3.87K ﹤0.01% 3011
2023
Q3 		$267K Sell
26,532
-246
-0.9% -$2.84K ﹤0.01% 2989
2023
Q2 		$318K Sell
26,778
-71
-0.3% -$949 ﹤0.01% 2971
2023
Q1 		$325K Buy
26,849
+1,158
+5% +$19.3K ﹤0.01% 2586
2022
Q4 		$338K Buy
25,691
+111
+0.4% +$1.63K ﹤0.01% 2630
2022
Q3 		$346K Buy
25,580
+1,678
+7% +$22.4K ﹤0.01% 2669
2022
Q2 		$292K Buy
23,902
+7,686
+47% +$91K ﹤0.01% 2767
2022
Q1 		$233K Buy
16,216
+5,179
+47% +$84.7K ﹤0.01% 2719
2021
Q4 		$218K Sell
11,037
-73
-0.7% -$1.53K ﹤0.01% 2812
2021
Q3 		$240K Buy
+11,110
New +$320K ﹤0.01% 2848

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

RhumbLine Advisers's JANX Position: Q2 2026 in Review

RhumbLine Advisers increased its Janux Therapeutics (JANX) stake by 4.9% in Q2 2026, buying an estimated $37.4K and bringing the position to 55,221 shares worth $848K. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

RhumbLine Advisers first reported a position in JANX in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.04M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • RhumbLine Advisers held 55,221 shares of Janux Therapeutics worth $848K as of Q2 2026.
  • RhumbLine Advisers bought 2,584 Janux Therapeutics shares in Q2 2026, an estimated $37.4K.
  • Janux Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2421 holding.
  • RhumbLine Advisers first reported a position in Janux Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • RhumbLine Advisers's Janux Therapeutics position peaked at $2.04M in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.